

A 2nd generation Next-Generation Sequencing Epigenomic test using Whole Transcriptome Sequencing (WTS) to advance precision medicine for patient care









Alternate Promoter Score (APS)

Gene Expression





6-8 Weeks Turnaround Time

Alternate Isoform Expression Level

Gene Fusion Occurrences



Reporting Components



Proprietary algorithm that predicts for cancer patients' response to immunotherapy



Gene Expression Level Potentially identify dysregulated genes that are associated with targeted therapies



Alternate Isoform Expression Level Identify alternate isoforms that are associated with potential treatment options



Gene Fusion Occurrences

Identification of genome-wide gene fusion occurrences to match with targeted cancer treatments

EPI-CALL™ serves to support clinicians in making informed decisions when it comes to therapy selection and optimising treatment outcomes for your patients.

EPI-CALL™ is suitable for multiple tumour types, but not limited to the following:



Gastric Cancer



Colorectal Cancer



Hepatocellular Carcinoma



Renal Cell Carcinoma



Oesophageal Cancer



Gynecologic Cancer



Breast Cancer



Others

Sample Requirements



Provide 10 to 15 unstained FFPE slides (5µm thick each)



Provide 1 matching H&E stained slide



For more information on how EPI-CALL™ can support therapy selection, contact us at:

Contact:

enquiry@auristone.com www.auristone.com

Address:

73 Ayer Rajah Crescent #02-19 S(139952)

